Human Endogenous Metabolite

Smilagenin (intragastric administration; 10 or 26 mg/kg, once daily; 60 days) prevents the impairment of dopaminergic neurons in chronic MPTP/probenecid-induced mouse model. Animal Model: MPTP/probenecid-induced mouse model Dosage: 10 or 26 mg/kg Administration: Intragastric administration; 10 or 26 mg/kg; once daily; 60 days Result: Ameliorated locomotor ability of MPTP/probenecid-lesioned mice.

Smilagenin (10 μM; 24 hours) increases SH-SY5Y cell survival compared with Aβ(25-35) intoxicated cells. Smilagenin (10 μM; 24 hours) increases neurotrophic factor (GDNF) and neurotrophic factor (BDNF) mRNA level by promoting CREB phosphorylation in 1-methyl-4-phenylpyridimium (MPP + ) treated SH-SY5Y cells. Cell Viability Assay Cell Line: SH-SY5Y cells Concentration: 10 μM Incubation Time: 24 hours Result: Elevated the SH-SY5Y cell viability. RT-PCR Cell Line: SH-SY5Y cells Concentration: 10 μM Incubation Time: 24 hours Result: Increased GDNF and BDNF transcription.

Smilagenin (SMI) 是一种脂溶性小分子甾体皂苷元，来自知母 Rhizoma anemarrhenae 和天竺葵 Radix asparagi，广泛用于慢性神经退行性疾病的研究。Smilagenin (SMI) 通过增加毒蕈碱受体亚型 1 (M1)-受体的的密度来改善老年大鼠的记忆。 Smilagenin (SMI) 通过刺激脑源性神经营养因子的基因表达减弱 Aβ (25-35) 诱导的神经变性，可用于 AD 的研究。